Virtual Workshop: Exploring Opportunities and Feasibility of Trials on Effects of Increasing NAD+ Levels in Older Adults

Virtual Workshop: Exploring Opportunities and Feasibility of Trials on Effects of Increasing NAD+ Levels in Older Adultsbroderickjs@nih.govNovember 18, 2021Division Announcements Aging Biology Clinical Research Geroscience

Date: December 9, 2021 from 10am-5:45pm, ET

Sponsored by: NIA's Division of Geriatrics and Clinical Gerontology

Registration Information

10:00am-10:05am: Welcome and Introductions

10:05am-10:15am: Charge to Participants

10:15am-12:20pm:Session 1: Aging and NAD+ Level

10:15am-11:15am: Role NAD+ and Aging
- 11:15am-10:45am: NAD precursors in humans, David Sinclair, Harvard University
- 10:45am-11:15am: Dysregulation of the NAD System in Conditions of Metabolic Stress: Mechanisms of NAD Attack and Mechanisms of Boosted Resiliency, Charles Brenner, City of Hope National Medical Center, Duarte, California
11:15am-11:40am: The NAD World 3.0: the importance of the inter-tissue communication in mammalian aging and longevity control, Shin-Ichiro Imai, Washington University
11:40am-12:00pm: NAD supplementation in diseases with DNA repair deficiency, Vilhelm Bohr, National Institute on Aging, NIH
12:00pm-12:20pm: Novel neuroimaging approaches to measure in vivo NAD+ and NADH, Fei Du, McLean Hospital

12:20pm-12:50pm: Break

12:50pm-2:10pm: Session II: Therapeutic Targets for Boosting NAD+ in Aging

12:50pm-1:10pm: NAD precursors cycle between the host and gut microbiome, Joseph Baur, University of Pennsylvania
1:10pm-1:30pm: CD38 as a therapeutic target, Eduardo Chini, Mayo Clinic
1:30pm-1:50pm: Normalization of NAD+ redox balance as a therapy for heart failure, Rong Tian, University of Washington
1:50pm-2:10pm: Mitochondrial nutrient sensing as a target for therapeutic intervention, Michael Zemel, NuSirt Biopharma & Kinexum

2:10pm-2:40pm: Break

2:40pm-3:40pm: Session III: Clinical Experience Targeting NAD Therapeutically

2:40pm-3:00pm: Clinical evidence for targeting NAD therapeutically. Review of completed clinical trials for NAD+ boosting, Eric Verdin, Buck Institute for Research on Aging
3:00pm-3:20pm: Safety and metabolism of long-term administration of nicotinamide riboside, Andrew Shao, ChromaDex Inc.
3:20pm-3:40pm: Nicotinamide riboside supplementation for alleviating vascular aging, Douglas Seals, University of Colorado

3:40pm-4:00pm: Break

4:00pm-5:45pm: Session III: Clinical Experience Targeting NAD Therapeutically (Continued)

4:00pm-4:20pm: NAD+ boosting compounds to improve memory and cerebrovascular function, Christopher Martens, University of Delaware
4:20pm-4:40pm: Sirtuin-NAD activators in COVID-19 infection, Shally Bhasin, Brigham and Women's Hospital, Harvard University
4:40pm-5:00pm: Effect of nicotinamide mononucleotide (NMN) on cardiometabolic function, Samuel Klein, Washington University
5:00pm-5:45pm: Group Discussion: What should we try to treat or prevent and who is the target population(s)? What types of trials are feasible and needed?